Humana (HUM) Launches Cancer Care Model, Is The Stock Still Trading At A Discount?

Humana (HUM) has put cancer care at the center of its story this month, rolling out a new model with Evolent Health and American Oncology Network that trims prior authorization friction using data and performance incentives.

Humana’s recent news comes during a strong run in the shares, with a 90 day share price return of 15.67% and a year to date share price gain of 70.15% lifting the latest close to US$450.00.

The launch of the cancer care model and prior authorization partnerships has coincided with this upswing, while a 1 year total shareholder return of 92.25% contrasts with a 3 year total shareholder return that declined 6.28%. This hints at momentum that has only really gathered pace over the past year.

Spot similar healthcare momentum stories by scanning our hand-picked 36 healthcare AI stocks, which are also leaning on data, automation and smarter care pathways.

After a 92% 1 year total return and fresh headlines around Humana’s cancer care push, the question now is simple: Does the current valuation still leave enough upside to justify new risk?

Most Popular Narrative: 5% Undervalued

On the Simply Wall St analyst consensus Narrative, Humana’s fair value sits at $475.54, a touch above the latest $450.00 close. This frames today’s price as modestly below that modelled worth and sets up the key assumptions behind it.

The main thing that has to go right is that Humana delivers on its multiyear Medicare Advantage margin and cost-transformation program, including disciplined plan pruning, operating cost ratio reductions, and effective value-based partnerships, while managing regulatory and compliance risks.

The current narrative that Humana is fairly valued and bullish implies the share price already reflects meaningful progress on margin restoration, operating cost efficiencies, and balance sheet optimization with limited room for disappointment if these plans slip.

See why 62 investors see Humana as 5% undervalued.

Result: Fair Value of $475.54 (UNDERVALUED)

Still, the Humana story carries real pressure points, including any setback in Medicare Advantage margin restoration or tighter oversight of diagnosis coding and Stars-related reimbursement.

Find out about the key risks to this Humana narrative.

Next Steps

Plenty of investors see both risk and reward in Humana right now, so move quickly, review the underlying data, and weigh the 2 key rewards and 2 important warning signs.

Looking for more Humana sized opportunities?

If Humana has your attention, do not stop here. Use Simply Wall St screeners to spot other ideas that match your risk, income, and quality preferences.

• Target potential mispricing across the market by reviewing stocks in our 32 high quality undervalued stocks that combine appealing valuations with stronger fundamentals.
• Strengthen your income stream by assessing companies in the 6 dividend fortresses that focus on higher yields with an emphasis on resilience.
• Dial down portfolio risk by filtering for companies in the 31 resilient stocks with low risk scores that score well on balance sheet strength and overall stability.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com